Mao Inhibitors + Mirvetuximab Soravtansine Interaction
Moderateinteraction on record
Description
Concomitant use may increase unconjugated DM4 exposure, increasing the risk of ELAHERE adverse reactions. Closely monitor patients for adverse reactions.
Mechanism
DM4 is a CYP3A4 substrate; strong CYP3A4 inhibitors may increase unconjugated DM4 exposure
Source: NLP:mirvetuximab soravtansine